PDCD1 and metabolic dysfunction-associated steatotic liver disease: identify that targeting METTL3 by small-molecule inhibitor STM2457 or nanoparticle siMETTL3 can induce a robust antitumor immune response, leading to the regression of NAFLD-HCC tumors when used in conjunction with anti-PD-1 therapy.